From Medscape Neurology

Highlights of the 8th International Conference on Alzheimer's and Parkinson's Diseases

Salzburg, Austria, March 14-18, 2007

Keith R. Edwards, MD

Posted: 05/01/2007

 

processing....

 

Introduction

The biannual Alzheimer's and Parkinson's Disease meeting this year was entitled: Progress and New Perspectives. There were 2 main topics: Modeling Neurodegenerative Diseases in Vivo and a Clinical Drug Trial Section. The basic science section represented the majority of the presentations with emphasis on new information with some summary presentations of recently published material. All of the abstracts are published in The Journal of Neurodegenerative Disease 2007;4:1-364, or are online at www.karger.com/ndd.

This meeting is of special interest to scientists, clinicians, and those in industry who are involved with not only each of these major neurodegenerative diseases, but especially in the increasing awareness of the interplay that amyloid, alpha-synuclein, tau, microglia, genetic, and environmental factors have in the spectrum of the tauopathies, synucleopathies, and amyloidopathies.

 
Section 1 of 7
[ CLOSE WINDOW ]

References

  1. Schenk D, Seubert P, Games D, et al. A immunotherapy: use of monoclonal antibodies for potential treatment and amelioration of AD neuropathy. Neurodegener Dis. 2007;4:13.
  2. Nicoll J. Potential mechanisms of abeta plaque clearance in patients immunized with Abeta. Neurodegener Dis. 2007;4:14.
  3. Brooks DJ. Imaging amyloid and inflammation in Alzheimer's disease, Parkinson's disease dementia (PDD) and Lewy body dementia (LBD). Neurodegener Dis. 2007;4:185.
  4. Rockenstein E, Buttini M, Games D, Schenk D, Masliah E. Alpha-synuclein clearance and vaccination strategies in the development of new treatments Parkinson's disease. Neurodegener Dis. 2007;4:14.
  5. Hock C, Steffer J, Kollias S, Buck F, Haenggi J, Henke K, Nitsch R. AD biomarkers and neuroimaging in treatment evaluation. Neurodegener Dis. 2007;4:110.
  6. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris J, Holtzman D. Cerebrospinal fluid biomarkers of early stage Alzheimer's disease. Neurodegener Dis. 2007;4:110.
  7. Feldman H, Sparks DL, Doody R, et al., T.H.E. LEAD-e Investigators. Design and baseline data for a study of Lipitor's effect in Alzheimer's dementia (Lead-e). Neurodegener Dis. 2007;4:333.
  8. Barone P, Hsu C, Tekin S, Lane R. Effect of hyperhomocysteinaemia on response to rivastigmine in patients with Parkinson's disease dementia. Neurodegener Dis. 2007;4:51.
  9. Korczyn AD. Alzheimer's disease and vascular dementia. Neurodegener Dis. 2007;4:101.
  10. Gauthier S. Treatment options for Alzheimer's disease. Neurodegener Dis. 2007;4:102.
[ CLOSE WINDOW ]

 

[CLOSE WINDOW]

Authors and Disclosures

Keith R. Edwards, MD, Assistant Clinical Professor of Neurology, Harvard Medical School, Boston, Massachusetts; Consulting Neurologist, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Disclosure: Keith R. Edwards, MD, has disclosed that he has served as an advisor or consultant to Allergan Pharmaceuticals, GlaxoSmithKline, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and Serono.

 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC. This website also contains material copyrighted by 3rd parties.